Results 1 to 10 of about 103,365 (348)
Equine glucagon-like peptide-1 receptor physiology [PDF]
PeerJ, 2018 Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased ...
Murad H. Kheder +4 more
doaj +5 more sources
How glucagon-like peptide 1 receptor agonists work [PDF]
Endocrine Connections, 2021 In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show ...
Christine Rode Andreasen +3 more
doaj +5 more sources
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias [PDF]
Journal of ArrhythmiaBackground Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal +12 more
doaj +2 more sources
Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea [PDF]
Obesity Science & PracticeBackground and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian +4 more
doaj +2 more sources
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists [PDF]
Endocrinology and Metabolism, 2016 Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade.
Yu Mi Kang, Chang Hee Jung
doaj +3 more sources
Nephroprotective potential of glucagon-like peptide-1 receptor agonists [PDF]
Сахарный диабет, 2020 Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources.
Minara S. Shamkhalova +2 more
doaj +2 more sources
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2017 The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj +3 more sources
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
Journal of DiabetesGlucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac +2 more
doaj +3 more sources
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
Frontiers in EndocrinologyGlucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids.
Lisan Ji +8 more
doaj +3 more sources
Frontiers in Endocrinology, 2021 ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong +12 more
doaj +1 more source